Clinical Trial Update: Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III [Phase 3]

View source ↗

Summary

Phase 3 trial update on danoprevir/r plus PR 12-week triple therapy in treatment-naive non-cirrhotic genotype 1 chronic hepatitis C showed completed results wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Danoprevir/r (danoprevir/ritonavir)
• PR

Snippet

Sponsor: Ascletis Pharmaceuticals Co., Ltd. | Conditions: Chronic Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2021-03-23